Parmax Pharma Ltd vs Vineet Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Parmax Pharma Ltd is ₹ 30.02 as of 30 Apr 15:30 . The P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Vineet Laboratories Ltd changed from 6.6 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 yearsThe Market Cap of Vineet Laboratories Ltd changed from ₹ 43.7 crore on March 2022 to ₹ 28.06 crore on March 2025 . This represents a CAGR of -10.48% over 4 years The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 4.33 crore as compare to the Sep '25 revenue of ₹ 2.54 crore. This represent the growth of 70.47% The revenue of Vineet Laboratories Ltd for the Dec '25 is ₹ 15.7 crore as compare to the Sep '25 revenue of ₹ 17.43 crore. This represent the decline of -9.93% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ -0.19 crore as compare to the Sep '25 ebitda of ₹ -1.58 crore. This represent the decline of -87.97% The ebitda of Vineet Laboratories Ltd for the Dec '25 is ₹ 2.54 crore as compare to the Sep '25 ebitda of ₹ 3.18 crore. This represent the decline of -20.13% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ -0.73 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Vineet Laboratories Ltd changed from ₹ -2.13 crore to ₹ 0.85 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vineet Laboratories Ltd changed from 13.89 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

About Vineet Laboratories Ltd

Vineet Laboratories Limited, formerly known as Ortin Laboratories Limited is a manufacturing company of intermediates useful for the manufacture of active pharmaceutical ingredients.
The Company was incorporated on 10 November 2016 and operates in the business of in the manufacture of Drug Intermediates & Bulk Dugs.
The name of the Company changed to Vineet Laboratories Limited, on account of demerger in December, 2020. The production unit located at Malkapur Village, Yadadri- Bhuvanagiri District in Telangana State, India, is a multipurpose facility well equipped with stainless steel and glass-lined reactors with total volume of 230KL, of different volumes to suit any batch size.
Special provisions are made to carry out reactions at very low temperature (up to -100°C).
The Company is also specialized in manufacturing and handling pyrophoric chemicals like n-Butyl Lithium.

FAQs for the comparison of Parmax Pharma Ltd and Vineet Laboratories Ltd

Which company has a larger market capitalization, Parmax Pharma Ltd or Vineet Laboratories Ltd?

Market cap of Parmax Pharma Ltd is 11 Cr while Market cap of Vineet Laboratories Ltd is 73 Cr

What are the key factors driving the stock performance of Parmax Pharma Ltd and Vineet Laboratories Ltd?

The stock performance of Parmax Pharma Ltd and Vineet Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Parmax Pharma Ltd and Vineet Laboratories Ltd?

As of May 4, 2026, the Parmax Pharma Ltd stock price is INR ₹30.02. On the other hand, Vineet Laboratories Ltd stock price is INR ₹38.1.

How do dividend payouts of Parmax Pharma Ltd and Vineet Laboratories Ltd compare?

To compare the dividend payouts of Parmax Pharma Ltd and Vineet Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.